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Respiratory delivery is at present the normal route of 
administration of drugs for respiratory diseases, and this 
is accomplished by the use of a variety of devices such as 
metered dose inhalers (MDls), dry powder inhalers 
(DPls) and nebulizers, all of which have their place in 
treatment. 
Nearly 80% of asthmatic patients worldwide use MDls. 
Their popularity is due to a number of factors.They are 
small, portable and easy-to-use devices. Furthermore, the 
design of all types of MDls is similar. Hence there is a 
familiarity and usually less need for education compared 
with DPls where each company produces a unique 
design with varying operating principles and instructions. 
Dose consistency of MDls is good with the energy for 
delivering the dose being constant (the evaporating 
propellant) unlike DPls where the dose may vary with 
the patient’s inspiratory flow effort. 
Chlorofluorohydrocarbons (CFCs) have been used 
widely in many products of the industrialized world 
(general aerosols, e.g. hairsprays, toiletries, etc; 
refrigeration, plastics); they are also used in MDls and 
other types of pharmaceutical aerosol. Their discharge 
into the atmosphere has led to a depletion of the ozone 
levels with consequent environmental threats. The 
Montreal Protocol was drafted by the United Nations 
Environmental Programme in 1987 in response to the 
alarming situation. Production of CFCs was halted in the 
developed world in 1996 except for ‘essential users’ 
which include MDls. Efforts to eliminate the need for 
CFCs even in these ‘essential’ applications have 
continued and the European Commission, in its 
document Strategy for the Phase-Out of CFCs in Metered 
Dose Inhalers [COM (1998) 603 Final] published on 23 
October 1998, has set a target date of 2005 for the 
withdrawal of CFC-based inhalers. 
The search for new and ‘ozone friendly’ propellants 
covered a number of alternatives such as hydrocarbons 
(butane, pentane) but soon concentrated on two 
hydrofluoroalkanes (HFAs), first HFA l34a and then 
HFA 227. They have suitable physicochemical properties 
which are similar to the CFCs they replace. 
Major formulation changes were needed and in many 
cases the only common ingredient between CFC and 
HFA products is the drug, with all excipients being 
changed. CFCs and HFAs share a number of basic 
technical characteristics but differ in such physical 
properties as density, vapour pressure, molecular 
polarity and evaporation kinetics. These differences 
have necessitated the development of new formula- 
tions, valves and manufacturing processes for HFA I34a 
inhalers. 
The reformulation of CFC MDls with ozone-friendly 
propellants (HFAs) has proved much more difficult than 
originally envisaged and the pharmaceutical industry is 
still investing significant resources in the development of 
the new generation MDls. 
Modulite@ has been developed by the Chiesi Group to 
solve the technical problems associated with the phase- 
out of CFCs and their replacement with HFAs. Key 
advantages of the Modulite@ technology are stable and 
uniform dose delivery of HFA-based formulations and 
flexibility in tailoring the particle size distribution of the 
cloud generated on actuation of the MDI. 
Particle size is a critical factor in aerosolized drug 
delivery, affecting both the dose quantity and delivery 
site, and hence clinical efficacy and tolerability. Different 
regions of the lungs can be targeted modulating the 
dimension of the particles. 
This principle can be applied to HFA formulations in 
two ways: 
?? It is possible to generate clouds closely matching 
particle size and drug mass of current CFC suspension 
formulations (seamless transition), 
?? Formulation can be refined to remove unwanted cloud 
components: i.e. products with a reduced nominal 
dose and a larger percentage (70-80%) of clinically 
useful product and with defined particle size targeting 
specific lung areas. 
Modulite@ HFA technology allows an easy transition to 
CFC-free products and may also be exploited to improve 
the performance of MDls or develop new formulations 
with original cloud characteristics according to the 
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clinical profile of the drug to be administered. It can be 
envisaged that in the future, Modulite@ HFA technology 
may also be applied to the delivery via the lungs of non- 
pulmonary drugs. 
The first practical result of the application of the 
Modulite@ technology to pharmaceuticals are new 
formulations of beclomethasone dipropionate (BDP) 
with HFA l34a. The development programme has 
covered four products containing 50 ug, IO0 pg, 200 yg 
or 250 ug per actuation of BDP in inhalers delivering 200 
actuations. The products have been designed to be 
equivalent in terms of efficacy, safety and dose delivered 
to currently marketed CFC-containing inhalers that 
provide the same amount of BDP per actuation, so as to 
allow seamless transition to CFC-free MDI treatment, 
minimizing anxiety and concerns in patients and their 
families when changing their current asthma medications 
based on CFC. 
This supplement of Respiratory Medicine presents an 
overview of the technical and clinical aspects of the 
Modulite@ technology. 
In the first paper D. Ganderton et al. explain how 
Modulite@ has been developed taking advantage of the 
phasing-out of CFC MDls to design a new and improved 
MDI.The emission of clouds of particles with a chosen 
size and plume speed with Modulite@ was possible by the 
addition of glycerol as a non-volatile excipient to the 
formulation and by modifying the geometry of the 
actuator orifice. The practical result is that Modulite@ 
generates clouds closely matching particle size and drug 
mass of current CFC formulations, thus maintaining 
established dose schedules and promoting a ‘seamless 
transition’. 
In the second paper, A. Woodcock et al. illustrate the 
pharmacokinetic and pharmacodynamic characteristics 
of Modulite@. Studies conducted in healthy volunteers, as 
well as in asthmatic patients, demonstrate that BDP and 
budesonide Modulite@ did not produce significantly 
different effects on serum cortisol or urinary cortisol 
excretion at high daily doses, compared with the CFC 
products. Also, the systemic exposure measured by 
plasma levels of B,,MP the active metabolite of BDP, was 
comparable between BDP Modulite@ and BDP-CFC and 
was substantially less than that obtained with a different, 
extrafine HFA formulation of BDPThese studies confirm 
that BDP Modulite@ can replace the old BDP-CFC with- 
out the need to change the daily dose of inhaled drug. 
The opportunity offered by BDP Modulite@ to replace 
the BDP-CFC without the necessity to adjust patient’s 
dosing schedule was proved in five clinical studies 
involving I I58 asthmatic patients, both adults and 
children and with different grades of disease severity. J. 
Bousquet and L. Cantini review those studies in the last 
paper of this review. Studies were conducted comparing 
BDP Modulite@ with BDP-CFC and demonstrated 
similarity of efficacy on the main variables of assessment” 
The safety of the new BDP Modulite@ was also equiva- 
lent to that of the CFC-based product. 
The results of the development programme 
demonstrate that Modulite@ represents a good 
opportunity in this period of change from the traditional 
MDls to new and improved HFA MDls. 
